Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT on merger of FocusVision and Confirmit
Mandate

Vinge advises EQT on merger of FocusVision and Confirmit

January 08, 2021 Employment and Benefits Banking and Finance EU, Competition and Regulatory M&A

The Nordic-based PE-forms EQT and Verdance intends to merger their respective portfolio companies FocusVision and Confirmit.

FocusVision was acuiered by EQT 201t and provides software and services for market research. Confirmit was acquired by Verdane 2019 and provides solutions for, inter alia, customer experience and market research. The merger is subject to customary regulatory approvals. 

Vinge’s team consisted of partners Christina Kokko (M&A), Marcus Glader (EU & Competition) and Albert Wållgren (Banking & Finance) and associates Stina Bengtsson (M&A), Pauline Lagerstrand, (Banking & Finance), Ebba Svenburg (Employment), Emma Johansson, Sebastian Örndahl, Anna Grigorian, Xandra Ståhlberg and Alice Noguier (EU & Competition).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025